Merck whole eight weeks of oral triple therapy regimen HCV success rate> 90%

2015 Annual Meeting of the American Association for Study of Liver Diseases (AASLD 2015) was held in San Francisco on 13-17 of this month. Recently, Merck (Merck & Co) in conference to announce the company's two kinds of experimental research of the whole oral, triple Hepatitis C therapy (grazoprevir / MK-36822 / elbasvir, grazoprevir / MK-3682 / MK-84084) of 2 randomized, open-label phase II study (C-CREST 1, C-CREST 2) of Part A data. Wherein, C-CREST 1 study in naïve, non-cirrhotic hepatitis C genotype 1 and genotype 2 (HCV GT-1, GT-2) in patients with conduct, C-CREST 2 study in naïve, non-cirrhotic genotype 3 hepatitis C (HCV GT-3) conducted in patients. Institute recruited 240 patients completed the 8-week treatment and follow-up of 12 weeks after the end of treatment, the primary endpoint is virologic response 12 weeks (SVR12, virological cure). 2 kinds of hepatitis Full oral triple therapy, grazoprevir (MK-5172) is an HCV NS3 / 4A protease inhibitor, MK-3682 is an oral prodrug HCV NS5B nucleoside analog protease inhibitors, elbasvir (MK- 8742) and MK-8408 were HCV NS5A replication complex inhibitor.
Data show that the whole oral triple therapy (grazoprevir / MK-3682 / MK-84084) for 8 weeks treatment programs across the hepatitis C genotype 1, 2 groups of viral cure rates (SVR12) exceeds 90%, the study strong efficacy data observed to support the further continue to explore this novel all-oral HCV triple therapy efficacy and safety in the hepatitis C population. Currently, Merck has launched the Part B study grazoprevir / MK-3682 / MK-84084 triple therapy CREST II clinical development project, will investigate the efficacy and safety of the triple therapy treatment cycle in a variety of different patient populations, including early Hepatitis C treatment (with or without), HIV / HCV co-infection, (pegylated interferon / ribavirin) after hepatitis C treatment.